Author

William Sandborn 1

1 University of California San Diego,La Jolla,United States

EFFICACY AND SAFETY OF A NEW VEDOLIZUMAB SUBCUTANEOUS FORMULATION FOR ULCERATIVE COLITIS: RESULTS OF THE VISIBLE 1 PHASE 3 TRIAL

William Sandborn, Filip Baert, Silvio Danese, Željko Krznarić, ;Geert R. D'Haens, Taku Kobayashi, Xiaopan Yao, Jingjing Chen, Krisztina Kisfalvi, Severine Vermeire

EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE ?SEVERE CROHN?S DISEASE PATIENTS: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

Bruce E. Sands, Christopher Gasink, Douglas Jacobstein, Long Long Gao, Jewel Johanns, Philippe Szapary, Jean-Frederic Colombel, Stephan Targan, Subrata Ghosh, William Sandborn

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan, Edward V. Loftus, Jr., Silvio Danese, Severine Vermeire, William Sandborn, Tim Ritter, Rajiv Mehta, Ursula Seidler, Frank Seibold, Ian Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, Stefan Schreiber, Gerhard Rogler, Toshifumi Hib

EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet, Edward V. Loftus Jr., Silvio Danese, Severine Vermeire, William Sandborn, Ronald Fogel, Sandeep Nijhawan, Radoslaw Kempinski, Rafal Filip, Ihor Hospodarskyy, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, Stefan Schreiber, Gerhard Rogler, Toshi

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB (LY3074828) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS IN A PHASE 2 STUDY

William Sandborn, Geert R. D'Haens, Marc Ferrante, Raj Bhandari, Elina Berliba, Brian G. Feagan, Janelle Laskowski, Stuart Friedrich, Jay Tuttle, Michael Durante

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Geert R. D'Haens, Maria T. Abreu, Ruth Belin, Elisa Gomez Valderas, Debra Miller, April Naegeli, Vipin Arora, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Geert R. D'Haens, Taku Kobayashi, Nathan Morris, Trevor Lissoos, Amy Hoover, Xingyuan Li, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands

EFFICACY AND SAFETY OF OPEN-LABEL MAINTENANCE THERAPY WITH SUBCUTANEOUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE

Brian G. Feagan, Julian Panés, Marc Ferrante, Arthur Kaser, Geert R. D'Haens, William Sandborn, Edouard Louis, Markus Friedrich Neurath, Denis Franchimont, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Christian Selinger, Steven J Padula, Ivona Herichova, Anne M. Robinson, Kori Wallace, Jun Zhao, Adina Soaita, Sudha Visva

EFFICACY AND SAFETY OF RE-INDUCTION TREATMENT WITH THE SELECTIVE IL-23 INHIBITOR RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN?S DISEASE

Brian G. Feagan, William Sandborn, Julian Panés, Marc Ferrante, Edouard Louis, Geert R. D'Haens, Denis Franchimont, Arthur Kaser, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Markus F. Neurath, Paul Scholl, Sudha Visvanathan, Steven J Padula, Ivona Herichova, Nanshi Sha, David Hall, Wulf O. Böcher

Item 51 - 60 / 206
1
...
3 4 5
6
7 8 9
...
21